Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

Medicine & Life Sciences

• bafetinib 100%
• bcr-abl Fusion Proteins 82%
• Leukemia 41%
• Imatinib Mesylate 32%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17%
• iroxanadine 12%
• Protein-Tyrosine Kinases 10%
• Therapeutics 8%
• Phase II Clinical Trials 6%
• Clinical Trials, Phase I 6%
• src-Family Kinases 6%
• Licensure 6%
• B-Cell Chronic Lymphocytic Leukemia 5%
• Cytogenetics 5%
• Precursor Cell Lymphoblastic Leukemia-Lymphoma 5%
• Point Mutation 5%
• Blood-Brain Barrier 5%
• Brain Neoplasms 5%
• Prostatic Neoplasms 4%
• Phosphotransferases 4%
• Mutation 3%
• Brain 2%
• In Vitro Techniques 2%

Chemical Compounds

• Imatinib 75%
• Tyrosine Kinase Inhibitor 70%
• Mutation 28%
• Cytogenetics 23%
• Resistance 10%
• Modification 9%